Press coverage about CareDx (NASDAQ:CDNA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CareDx earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.0018920197622 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Zacks: Brokerages Expect CareDx, Inc. (CDNA) Will Announce Quarterly Sales of $11.96 Million (americanbankingnews.com)
- CareDx, Inc. (CDNA) COO Mitchell J. Nelles Sells 10,948 Shares (americanbankingnews.com)
- 4 Top-Ranked Growth Stocks in MedTech Under $20 (finance.yahoo.com)
- Zacks: Analysts Anticipate CareDx, Inc. (CDNA) Will Announce Earnings of -$0.13 Per Share (americanbankingnews.com)
- ETFs with exposure to CareDx, Inc. : November 27, 2017 (finance.yahoo.com)
A number of research analysts recently commented on CDNA shares. HC Wainwright started coverage on CareDx in a research note on Monday, November 27th. They set a “buy” rating and a $12.00 price objective for the company. Craig Hallum restated a “buy” rating and set a $10.00 price objective (up from $4.00) on shares of CareDx in a research note on Monday, October 9th. Raymond James Financial upgraded CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Wednesday, September 27th. Zacks Investment Research upgraded CareDx from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Monday, September 4th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $7.00 price objective (up from $3.00) on shares of CareDx in a research note on Tuesday, September 26th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $7.75.
CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. The firm had revenue of $12.19 million during the quarter, compared to the consensus estimate of $12.05 million. CareDx’s revenue was down 2.3% on a year-over-year basis. equities analysts forecast that CareDx will post -0.83 earnings per share for the current fiscal year.
In other CareDx news, major shareholder Neil Gagnon purchased 10,642 shares of CareDx stock in a transaction on Thursday, October 5th. The stock was bought at an average price of $4.00 per share, for a total transaction of $42,568.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Mitchell J. Nelles sold 10,948 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $7.17, for a total value of $78,497.16. Following the transaction, the chief operating officer now owns 84,225 shares of the company’s stock, valued at approximately $603,893.25. The disclosure for this sale can be found here. Insiders own 5.40% of the company’s stock.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
What are top analysts saying about CareDx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CareDx Inc. and related companies.